XpresSpa Group Announces New Pilot Program in Collaboration with EL AL Israel Airlines for Pre-Flight COVID-19 Variant Testing Through XpresCheck Testing Facilities
August 03 2021 - 8:30AM
XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”),
a health and wellness company, today announced a collaboration
between XpresCheck and EL AL Israel Airlines, the national airline
of Israel. The new pilot program, launching on August 5, requires
negative COVID-19 PCR tests from passengers departing JFK
International Airport and arriving at Ben-Gurion International
Airport in Israel.
"We strive to do our best to make the passenger
process easier for our customers, especially during this time,”
said EL AL CEO, Avigal Soreq. “We are all aware that the virus is
here to remain in one form or another, so we adopted a different
approach, a ‘life alongside the coronavirus’ approach. EL AL is
doing everything in its power to continue developing solutions for
its customers, which will enable Israel to open up to foreign
tourism, A critical matter to the economy of the state of
Israel."
A negative COVID-19 PCR test is currently
required for passengers of all ages, including those vaccinated,
upon landing in Israel. Located in JFK T4, XpresCheck will collect
specimens for rapid molecular testing services to EL AL passengers
upon landing in Ben-Gurion International Airport to detect the
active presence of COVID-19 and reduce the risk of spreading the
virus.
“We look forward to collaborating with EL AL
Israel Airlines in our mutual efforts to provide flyers with more
accessible testing options to meet destination entry requirements
and improve variant tracking,” said Doug Satzman, XpresSpa CEO.
"Our approach will help streamline necessary
COVID-19 tests, while still maintaining safety and rigor
throughout the process. Once the pilot program
proves successful, we look to expand the EL AL relationship to
other US originating flights to Israel.”
About XpresSpa Group, Inc.
XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading
global health and wellness holding company operating three distinct
brands: Treat™, XpresCheck™, and XpresSpa™. Treat is a travel
health and wellness brand that will be providing on-demand access
to healthcare through technology and personalized services.
XpresCheck is a leading on-site airport provider of COVID-19
screening and testing with 13 locations in 11 domestic airports.
XpresSpa is a leading airport retailer of spa services and related
health and wellness products, with 43 locations in 21 airports
globally. To learn more about XpresSpa Group,
visit: www.XpresSpaGroup.com.
To learn more about Treat, visit: www.TreatCare.com.
To learn more about XpresCheck, visit: www.XpresCheck.com.
To learn more about XpresSpa, visit www.XpresSpa.com.
Twitter: @Treat_Care and Instagram: @treat_care
Twitter: @xprescheck and Instagram: @realxprescheck
Twitter @XpresSpa and Instagram: @XpresSpa
Forward-Looking Statements
This press release may contain "forward-looking"
statements within the meaning of Section 27A of the Securities Act
of 1933, and Section 21E of the Securities Exchange Act of 1934.
These include statements preceded by, followed by or that otherwise
include the words "believes," "expects," "anticipates,"
"estimates," "projects," "intends," "should," "seeks," "future,"
"continue," or the negative of such terms, or other comparable
terminology. In particular, these statements include, without
limitation, statements about our expectations relating to our new
XpresCheck™ concept, being able to expand testing to other
communicable diseases as well as administer vaccinations for the
seasonal flu, our positioning to be part of the national rollout of
various COVID-19 vaccinations as they become available, the degree
to which our public testing model assists passengers meet testing
requirements in select states and countries, our ability to
identify and gain access to the latest and best COVID-19 testing
methodologies and equipment, and our ability further expand our
initial sites and our overall ability to manage the regulatory
challenges associated with this business line.
Forward-looking statements relating to expectations about future
results or events are based upon information available to XpresSpa
Group as of today's date and are not guarantees of the future
performance of the company, and actual results may vary materially
from the results and expectations discussed. Additional information
concerning these and other risks is contained in XpresSpa Group’s
most recently filed Annual Report on Form 10-K, Quarterly Report on
Form 10-Q, recent Current Reports on Form 8-K and other Securities
and Exchange Commission filings. All subsequent written and oral
forward-looking statements concerning XpresSpa Group, or other
matters and attributable to XpresSpa Group or any person acting on
its behalf are expressly qualified in their entirety by the
cautionary statements above. XpresSpa Group does not undertake any
obligation to publicly update any of these forward-looking
statements to reflect events or circumstances that may arise after
the date hereof.
Investor Relations: ICR Raphael
Gross ir@xpresspagroup.com (203) 682-8253
Media: Julie Ferguson Julie@jfprmedia.com (312)
385-0098
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
XpresSpa (NASDAQ:XSPA)
Historical Stock Chart
From Sep 2023 to Sep 2024